Drug giant Bristol-Myers Squibb: Atazanavir moves into the spotlight while O83 bites the dust.
D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000458:organization & administration*; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D014481:United States
D017320:HIV Protease Inhibitors